Michael Cecchini, MD
Hematology & Oncology · New Haven, CTNPI 1184999336
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $72,891 of the $103,411 with a category attached, or 70.5%. It is spread thinly across 24 manufacturers, the largest accounting for just 14.1%. Among hematology & oncology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $833.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Seagen Inc.$13K
- Taiho Oncology, Inc.$10K
- Incyte Corporation$9K
- Beigene USA, Inc.$8K
- Ipsen Pharma SAS$8K
- plus $41K from 18 others
Across 1,029 payments — averaging $7450.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.8M
- Merck$1M
- Boehringer Ingelheim$732K
- Beigene, Ltd.$665K
- Mirati Therapeutics, Inc.$597K
- AstraZeneca$553K
- plus $2.3M from 16 others
What the payments were for
- Consulting fees$72,89170%
- Speaking & faculty fees$6,1816%
- Travel & lodging$20,72520%
- Food & beverage$3,6143%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $14,559 |
| Seagen Inc. | 9 | $12,843 |
| Taiho Oncology, Inc. | 5 | $10,208 |
| Incyte Corporation | 10 | $8,890 |
| Beigene USA, Inc. | 7 | $8,198 |
| Ipsen Pharma SAS | 5 | $7,906 |
| Daiichi Sankyo Inc. | 15 | $6,136 |
| Eisai Inc. | 10 | $5,850 |
| AbbVie | 13 | $5,751 |
| Regeneron | 9 | $4,974 |
| Agios Pharmaceuticals, Inc. | 6 | $3,792 |
| Astellas Pharma Global Development | 1 | $2,704 |
| Beone Medicines USA, Inc. | 2 | $2,497 |
| Eli Lilly | 4 | $1,915 |
| F. Hoffmann-la Roche AG | 5 | $1,888 |
| Boehringer Ingelheim International GmbH | 5 | $1,731 |
| Exelixis Inc. | 1 | $1,650 |
| Bayer | 1 | $1,526 |
| Astrazeneca AB | 1 | $135 |
| Janssen Scientific Affairs, LLC | 1 | $104 |
| Aroa Biosurgery Incorporated | 2 | $48 |
| Genentech USA, Inc. | 1 | $46 |
| Janssen Research & Development, LLC | 1 | $38 |
| Ardelyx, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$103,411 in reported general payments places this provider in the 95th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 20 | $539 |
| Dexamethasone | 12 | $199 |
| Oxycodone Hcl | 13 | $136 |
| LoperamideLoperamide Hcl | 17 | $112 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New Haven
- Amer ZeidanNew Haven$807K
- Walid ShaibNew Haven$217K
- Scott HuntingtonNew Haven$163K
- Nataliya UbohaNew Haven$124K
- Iris IsufiNew Haven$73K
- Maximilian StahlNew Haven$34K
- Shalin KothariNew Haven$24K
- John RobertsNew Haven$17K
- Biree AndemariamFarmington$646K
- Paul WeinsteinStamford$288K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.